|
Chemical
Name:
Pemoline Brand
Name:
Cylert Manufacturer:
Abbott
Laboratories Description:
A
central nervous system stimulant that is structurally dissimilar to the
amphetamines and methylphenidate. Indications
and Use: For
the management of Attention Deficit Hyperactivity Disorder. Contraindications,
Warnings and Precautions: Contraindicated
in persons with impaired hepatic function.
Because of its association with life threatening hepatic failure, Cylert
should not ordinarily be used as first line drug therapy for ADHD.
Since Cylert’s marketing in 1975, 13 cases of acute hepatic failure
have been reported to the FDA. Of
the 13 cases reported as of May 1996, 11 resulted in death or liver
transplantation, usually within four weeks of the onset of symptoms of liver
failure. Cylert may exacerbate
symptoms of thought disorder. There
have been reports of elevated liver enzymes associated with the use of Cylert.
Central nervous system stimulants have been reported to precipitate motor
and phonic tics and Tourette’s disorder. Decreased seizure threshold has been
reported in patients taking Cylert concomitantly with antiepileptic medications.
Cylert should be used with caution in emotionally unstable patients who may
increase the dosage on their own initiative because there have been isolated
reports of transient psychotic symptoms in adults following the long-term misuse
of excessive oral doses of pemoline. Psychological an/or physical dependence might occur with
Cylert. Adverse
Reactions:
Possible common side effects may include insomnia, decreased appetite,
Tourette’s disorder and elevated liver enzymes.
Less common side effects may include irritability, dizziness, headache,
stomach pain, and acute hepatic failure. Dosing
Range:
Recommended starting dose is 37.5mg per day.
The effective daily dose for most patients will range from 56.25 to 75mg
per day with a maximum recommended daily dose of 112.5mg.
|
|
These pages are solely for public informational purposes. The information cannot be relied on to make diagnoses or prescribe treatment in any individual. Persons who require such services should consult with a licensed professional. Send mail to ropa@redoakpsychiatry.com with questions or comments about this web site.© 2000 Red Oak Psychiatry Associates, P.A. Updated
11/26/2007
|